Pyruvate for Interference Testing Catalog # K2010008P Lot # Batch Dependent Expiration Batch Dependent Volume/Weight 1 mL pH Not applicable Supplied as Ready-to-use solution Appearance Clear solution Storage –20°C Keywords Sodium pyruvate Grade Biotechnology grade; ≥99% purity; 0.22 µm filtered This ready-to-use sodium pyruvate solution (20 mg/mL) is formulated for interference testing in biochemical and clinical assay workflows. Packaged in 1 mL aliquots, the clear solution is ideal for spiking into specimens to evaluate pyruvate’s impact on enzymatic reactions, metabolic profiling, and diagnostic assay performance. Its high purity (≥99%) and preparation with Type I ultrapure water (resistivity >18 MΩ·cm) ensure reproducibility and minimal background interference. Pyruvate plays a central role in cellular metabolism and is frequently encountered in blood, tissue, and culture media. This product enables researchers to simulate physiological or pathological concentrations of pyruvate and assess its influence on assay sensitivity, specificity, and linearity. Applications include mitochondrial function assays, lactate/pyruvate ratio studies, and interference benchmarking in enzymatic and spectrophotometric platforms. Key benefits: Ready-to-use sodium pyruvate solution (20 mg/mL) Validated for interference testing in clinical and biochemical assays High purity (≥99%) and ultrapure water formulation Stable at –20°C; single-use aliquots recommended Supports metabolic profiling and assay robustness studies Indication for Use:This product is for Research Use Only (RUO). This product is not for administration to humans or animals. This product is not for human or veterinary diagnostic or therapeutic use. All Interference Products Brochure Download PDF References:1: WEINSTEIN I, GUSS ML, ALTENBERN RA. Pyruvate oxidation by Pasteurella tularensis strains of graded virulence. J Bacteriol. 1962 May;83(5):1010-6.2: Chuang CK, Wang TJ, Yeung CY, Hsieh WS, Lin DS, Ho SC, Lin SP. Interference and blood sample preparation for a pyruvate enzymatic assay. Clin Biochem. 2006 Jan;39(1):74-7.3: Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion. 2015 Jan;20:34-42.4: Hibi M, Horinouchi N, Tu W, Soong CL, Ito M, Segawa T, Mu X, Hagishita T, Yokozeki K, Shimizu S, Ogawa J. Breeding of a cyclic imide-assimilating bacterium, Pseudomonas putida s52, for high efficiency production of pyruvate. Biosci Biotechnol Biochem. 2013;77(8):1650-4.5: HUCKABEE WE. Relationships of pyruvate and lactate during anaerobic metabolism. II. Exercise and formation of O-debt. J Clin Invest. 1958 Feb;37(2):255-63.6: MCMILLAN PJ, MORTENSEN RA. The metabolism of brain pyruvate and acetate in the tricarboxylic acid cycle. J Biol Chem. 1963 Jan;238:91-3.7: HUCKABEE WE. Relationships of pyruvate and lactate during anaerobic metabolism. III. Effect of breathing low-oxygen gases. J Clin Invest. 1958 Feb;37(2):264-71.8: GUGGENHEIM K, MAYER J. Studies of pyruvate and acetate metabolism in the hereditary obesity-diabetes syndrome of mice. J Biol Chem. 1952 Sep;198(1):259-65.9: Turner K, Martin KL, Woodward BJ, Lenton EA, Leese HJ. Comparison of pyruvate uptake by embryos derived from conception and non-conception natural cycles. Hum Reprod. 1994 Dec;9(12):2362-6.
